{"id":"W2994601580","doi":"10.1186/s13058-019-1240-y","title":"Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer","year":2020,"lang":"en","type":"erratum","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Trastuzumab; Neratinib; Medicine; Surgical oncology; Paclitaxel; Oncology; Breast cancer; Internal medicine; Chemotherapy; Neoadjuvant therapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008065309,0.002431281,0.002637963,0.002966967,0.00304677,0.004909157,0.003664053,0.008227109,0.05454431],"category_scores_gemma":[0.08606606,0.00142507,0.002284508,0.00270386,0.001891118,0.001849563,0.00141812,0.01789568,0.03640261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005849434,"about_ca_system_score_gemma":0.01004706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02356635,"about_ca_topic_score_gemma":0.03109824,"domain_scores_codex":[0.9937395,0.001415472,0.001158595,0.0007749645,0.002313462,0.000598034],"domain_scores_gemma":[0.9580014,0.01511548,0.002322864,0.001733486,0.01993715,0.002889631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.00003413182,0.000003711157,0.00002538489,0.00004575455,0.000007194931,0.00005801424,0.000006404933,0.00001612387,0.00001026019,0.0001812827,0.9980172,0.001594573],"study_design_scores_gemma":[0.0002609884,0.00004380031,0.0007597372,0.0006594874,0.00008131198,0.0003805593,0.00004735094,0.0002829864,0.000229615,0.001498454,0.9957082,0.00004747402],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.00006983661,0.0005916776,0.0003242086,0.09867211,0.8966225,0.00003016115,0.001586838,0.0001885227,0.001914189],"genre_scores_gemma":[0.005883584,0.005017136,0.00314,0.2899222,0.5602903,0.0003226763,0.002969108,0.001255119,0.1311999],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.05454431,"threshold_uncertainty_score":0.1824688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04353015785997257,"score_gpt":0.4212546769172177,"score_spread":0.3777245190572452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}